| Pharmacogenetics: from bench to byte—an update of guidelines JJ Swen, M Nijenhuis, A de Boer, L Grandia, AH Maitland‐van der Zee, ... Clinical Pharmacology & Therapeutics 89 (5), 662-673, 2011 | 1202 | 2011 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ... Clinical Pharmacology & Therapeutics 98 (1), 19-24, 2015 | 646 | 2015 |
| Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update JK Hicks, K Sangkuhl, JJ Swen, VL Ellingrod, DJ Müller, K Shimoda, ... Clinical pharmacology and therapeutics 102 (1), 37, 2017 | 612 | 2017 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ... Clinical Pharmacology & Therapeutics 103 (2), 210-216, 2018 | 517 | 2018 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants JK Hicks, JJ Swen, CF Thorn, K Sangkuhl, ED Kharasch, VL Ellingrod, ... Clinical Pharmacology & Therapeutics 93 (5), 402-408, 2013 | 515 | 2013 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants JK Hicks, JJ Swen, CF Thorn, K Sangkuhl, ED Kharasch, VL Ellingrod, ... Clinical Pharmacology & Therapeutics 93 (5), 402-408, 2013 | 515 | 2013 |
| Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process K E Caudle, T E Klein, J M Hoffman, D J Muller, M Whirl-Carrillo, L Gong, ... Current drug metabolism 15 (2), 209-217, 2014 | 430 | 2014 |
| Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and … KE Caudle, K Sangkuhl, M Whirl‐Carrillo, JJ Swen, CE Haidar, TE Klein, ... Clinical and translational science 13 (1), 116-124, 2020 | 424 | 2020 |
| Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing KE Caudle, CF Thorn, TE Klein, JJ Swen, HL McLeod, RB Diasio, ... Clinical Pharmacology & Therapeutics 94 (6), 640-645, 2013 | 396 | 2013 |
| DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ... The Lancet Oncology 19 (11), 1459-1467, 2018 | 329 | 2018 |
| Pharmacogenetics: from bench to byte JJ Swen, I Wilting, AL De Goede, L Grandia, H Mulder, DJ Touw, ... Clinical pharmacology & therapeutics 83 (5), 781-787, 2008 | 291 | 2008 |
| Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium CH van der Wouden, A Cambon‐Thomsen, E Cecchin, KC Cheung, ... Clinical Pharmacology & Therapeutics 101 (3), 341-358, 2017 | 289 | 2017 |
| Translating pharmacogenomics: challenges on the road to the clinic JJ Swen, TW Huizinga, H Gelderblom, EGE de Vries, WJJ Assendelft, ... PLoS medicine 4 (8), e209, 2007 | 234 | 2007 |
| Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group PCD Bank, KE Caudle, JJ Swen, RS Gammal, M Whirl‐Carrillo, TE Klein, ... Clinical Pharmacology & Therapeutics 103 (4), 599-618, 2018 | 227 | 2018 |
| Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization J Kevin Hicks, J J Swen, A Gaedigk Current drug metabolism 15 (2), 218-232, 2014 | 191 | 2014 |
| Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines CATC Lunenburg, CH van der Wouden, M Nijenhuis, ... European Journal of Human Genetics 28 (4), 508-517, 2020 | 182 | 2020 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 172 | 2023 |
| Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time CATC Lunenburg, LM Henricks, HJ Guchelaar, JJ Swen, MJ Deenen, ... European journal of cancer 54, 40-48, 2016 | 135 | 2016 |
| A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors A Yin, DJAR Moes, JGC van Hasselt, JJ Swen, HJ Guchelaar CPT: pharmacometrics & systems pharmacology 8 (10), 720-737, 2019 | 130 | 2019 |
| Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score LM Henricks, CATC Lunenburg, D Meulendijks, H Gelderblom, A Cats, ... Pharmacogenomics 16 (11), 1275-1284, 2015 | 125 | 2015 |
